Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HQP08 is a microbiome modulation formula, specifically a probiotic-based therapeutic, being developed by GenieBiome for the treatment of hair loss. The drug is designed to modulate the microbiota to address the underlying biological factors contributing to hair loss. It is currently in Phase 1 clinical development in collaboration with the Chinese University of Hong Kong (CUHK) and the Microbiota I-Center (MagIC).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HQP08.